Wednesday, 2 April 2014

Transparency Market Research, In Its Latest Report Projects that the Market for Organ Preservation Solutions will post a 16.5% CAGR through 2019

Transparency Market Research announced its new report on the Organ Preservation Solutions market that was first valued at USD 0.06 billion in 2012. However, the current market value is predicted to reach USD 204.9 million by 2019 at a CAGR growth rate of 16.5% for the market revenue forecast period 2013 to 2019.

An organ preservation solution is a method of preserving the organs of the body when they are not inside the body system. It is a medically proven technique of letting the organs become vulnerable to the exterior environment outside the human body. Hence, the organs that are removed from the human body are then preserved in specific adjustments using medical solutions. Organ preservation solutions have been playing a key role in increasing the number of organ transplants. They are intended for different purposes such as organ development of biologics and drugs, and organ transplant procedures and research.

Today, the medical industry has a growing demand for organ transplants in forms of different organ types including liver and kidney too. Such aspects are likely to infuse significant demand for organ preservation solutions in the long run.

The global market for organ preservation solutions has been predicted to grow at a CAGR rate of 16.5% during the forecast period 2013 to 2019. Moreover, it is projected to reach market revenue of USD 204.9 Million in the same forecast period. The Organ preservation solutions report studies the deep insights of this market and foresights every major solution for preserving organs. Amongst the proposed solutions, Viaspan and Custodiol are together accounted for over 75% of the total market share. During this market forecast period 2013 to 2019, the Custodiol market is predicted to rise and grow at a CAGR of 17.1%. 

The organ preservation solutions market is primarily driven by the rising incidences of organ failures in the patients due to changes in lifestyles such as fast food consumption, smoking, and alcohol, and increasing number of patients who are eagerly waiting to get an organ transplant done. The market also gets its popularity due to the rise in geriatric population, particularly in the developed regions such as U.K and U.S. All these conditions and locales are likely to propel the growth of this specific market. Another major reason for this growing sector is the rise in per capita healthcare expense and the advancing imbursement setups arranged for the organ transplant procedures in nations such as U.K, U.S., as well as now in India too.

Additionally, there are interesting techniques which are implemented to preserve the organs in the appropriate spaces. These include hypothermic perfusion preservation (HPP), static cold storage (SCS), and many others. Organ preservation solutions is extensively utilized for preserving different organs such as liver and kidney as it is highly capable of preserving a variety of organs unlike solutions such as HBS and Perfadex solution. 

Unlike the SCS that does not allow any continuous contact of the organ with solution, the HPP is a much better and adaptable technique to use. It is a machine perfusion process that maintains a constant supply to the organs needed by the solution whereby, the survival duration of the organs increases accordingly. The HPP market is anticipated to grow at a CAGR of 19.2% during the forecast period 2013 to 2019.

Earlier, in 2012, the European region had been accounted for the largest share of market revenue and until the present times, it still continues to prove its growth with a rate of 49.96% for 2012 (%). This is due to the presence of a large number of voluntary organ donors in this region. Nevertheless, other countries such as North America (42.23%), Asia-Pacific (5.66%), and RoW (2.15%) help propel the growth of the organ preservation solutions market as well.

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.


Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

Tuesday, 1 April 2014

As the life sciences industry becomes increasingly competitive while being pressured by regulatory mandates, business process outsourcing (BPO) is being considered as an effective way to improve operational performance.

The market for life sciences BPO is comprised of two distinct entities offering their services to biotech and pharmaceutical companies—Contract Research Organizations and Contract Manufacturing Organizations.

But what are the factors that have given rise to a demand for life science BPO services? The pharma industry is constantly grappling with patent expirations, a pressure to develop low-cost drugs, and the growing uncertainty in economic conditions. Companies in this domain thus need to approach their core operations with singular focus. This is where life science BPO enterprises come into the picture with their support services. Pharma companies outsource various functions and non-core operations to third parties with a view to streamlining their value chain and cutting costs.

These partnerships are usually forged in the form of long-term contracts and partnerships with CMOs and CROs. Through these partnerships, pharma companies share costs right from drug discovery and development to licensing to approvals with the CMOs and/or CROs.

Pharma companies are also experiencing effective outcomes via life science BPOs; the latter leverage their experience, trained professionals, and latest technology to the advantage of the former.

On the other hand, life-science BPOs too have been driven by the pressure to compete and achieve profitability. They try to accomplish this by introducing novel strategies to offer their clients a competitive advantage. According to a market research report published by U.S.-based market research firm Transparency Market Research, the global life sciences BPO market is projected to record a compounded annual growth rate (CAGR) of 21.5% between 2013 and 2019. 

Experts predict a healthy growth rate thanks to factors such as increased R&D investments by pharmaceutical companies, a spike in the demand for generic drugs, as well as a myriad of block buster drugs nearing the end of their patents. Other factors that have created a favorable environment for life science BPO include stringent regulatory mandates and government pressure to develop affordable drugs.

The Contract Manufacturing Organizations Market

According to the market research report published by Transparency Market Research, the CMO life science services outsourcing currently holds the largest share in the Life Sciences BPO market. The growth in healthcare costs has subsequently caused an increased generic drug demand, which has in turn led to a spike in the demand for the services of pharmaceutical outsourcing enterprises. Moreover, most CMOs have full-fledged R&D centers that employ novel technologies to give their clients an edge.

The market for active pharmaceutical ingredients (API) is the largest within the CMO segment. With mounting regulatory compliance and stringent approval parameters, the outsourcing of manufacturing activities to CMOs has received a boost.

At a time when manufacturers are striving to stay abreast of the latest regulatory mandates and industry breakthroughs, continually investing in facility upgrades might not be possible. This is another factor that can be attributed to the surge in demand for outsourcing partners as manufacturers do not possesses every required technology or expertise in-house. In such scenarios, outsourcing not only gives them access to the latest manufacturing technologies, but also proves to be a cost effective strategy.

The Contract Research Organizations (CRO) Market

Over the past decade, there has been considerable growth in the outsourcing services offered by CROs. Many pharmaceutical companies have been struggling to find a balance between mounting research costs and profitability. This has led many of these firms to turn towards CROs as a feasible option. The vendors operating in the market currently offer a combination of various services such as research, regulatory co-ordination services, data management, website management, medical writing, protocol development and others.

In 2012, the largest segment within this market was drug discovery. A report by Transparency Market Research however projects that between 2013 and 2019, the highest growth will be seen in the clinical data management BPO services at the rate of 17.3%.
Growth Projections

It is estimated that the Life Sciences BPO Market will be worth USD 596 billion worldwide by 2019, according to the Transparency Market Research report. And, while North America held the largest share in this market in 2012 with a worth of USD 28.4 billion, future growth is expected to be the highest in the Asia Pacific region with an approximate growth rate of 21.2% driven by various factors such as low cost of labor, availability of a talent pool, a large patient population, and comparatively favorable regulatory policies.